SR9009 Injection(Stenabolic) refers to the administration of SR9009 to experimental animals or research subjects in the form of injection. Compared with oral administration, injection can reach the peak blood drug concentration more quickly, but it may also increase the risk of local irritation and infection. When in use, the dosage and administration frequency should be strictly controlled. Excessive use may lead to serious side effects and health risks. When conducting scientific research experiments on this injection, the experimental plan should be reasonably designed, including the setting of the control group, the determination of the sample size, and the selection of observation indicators, etc. Meanwhile, ethical norms and animal welfare principles should be observed.This injection has strict requirements for storage and transportation conditions.
 |
 |
Stenabolic COA
Study on special disease model
SR9009 Injection is made into an injection form of the REV-ERBα/β agonist SR9009, which has important application value in the study of special disease models. The following is an introduction to its application in special disease models such as myocardial ischemia-reperfusion injury in type 2 diabetes, osteoarthritis, cognitive impairment related to sleep deprivation, and retinal pigment epithelium injury.
Application in Myocardial Ischemia-reperfusion Injury Models of Type 2 Diabetes Mellitus
Research background and purpose
Patients with type 2 diabetes often have cardiovascular complications, and myocardial ischemia-reperfusion injury is a common and serious pathological process among them. SR9009, as a REV-ERB agonist, has been studied for alleviating myocardial ischemia-reperfusion injury in type 2 diabetic rats. The aim is to evaluate the role of SR9009 in this disease model and its potential mechanism for regulating ferroptosis.
Experimental method
In the experiment, SPF-grade healthy male SD rats were selected. The rat model of type 2 diabetes was established by intraperitoneal injection of streptozotocin - citrate buffer. After the successful modeling, the rat myocardial ischemia-reperfusion injury model was prepared by ligating the anterior descending branch of the left coronary artery.
The experimental groups include the diabetic sham operation group, the diabetic myocardial ischemia-reperfusion group, the diabetic myocardial ischemia-reperfusion + SR9009 group, etc. The SR9009 group was intraperitoneally injected with SR9009 6 hours before ischemia.
Experimental results and conclusions
Compared with the diabetic myocardial ischemia-reperfusion group, the concentration of serum myocardial troponin I, the content of myocardial Fe²⁺ and MDA in the SR9009 group decreased, the activity of SOD increased, the expression of REV-ERB α was down-regulated, the expressions of SLC7A11 and GPX4 increased, and the myocardial infarction area decreased.
This indicates that pretreatment with the ReREV ERB agonist SR9009 of the clock gene can alleviate myocardial ischemia-reperfusion injury in type 2 diabetic rats, and is closely related to ferroptosis induced by abnormalities in the antioxidant system of the SLC7A11 / GPX4 axis.
Applications in the Cardiovascular Field: Targeting Rhythm and Inflammation to Block the Injury Cascade
SR9009 modulates circadian clock genes by activating Rev-Erb, suppressing inflammasomes and oxidative stress, demonstrating protective potential in scenarios such as myocardial ischemia-reperfusion injury, post-myocardial infarction remodeling, and viral myocarditis.
1.Myocardial ischemia-reperfusion injury (MI/R) and heart failure prevention
Core mechanism: Inhibiting myocardial NLRP3 inflammasome activation, reducing the release of pro-inflammatory factors such as IL-1β, decreasing neutrophil and macrophage infiltration, protecting myocardial fibroblast function, and mitigating infarct expansion and fibrosis PMC.
Research Evidence: In a mouse model of coronary artery ligation and reperfusion, a single post-reperfusion administration significantly reduced Nlrp3 mRNA and protein levels, decreased inflammatory factors, markedly improved long-term cardiac function within 1 day of treatment, and inhibited ventricular dilation and heart failure onset. The protective effect disappeared after Rev-Erb gene knockout, confirming the target specificity of PMC.
Application value: It provides a new approach of "time window therapy" for reperfusion injury after emergency PCI, where short-term intervention can block the inflammatory cascade and reduce the risk of long-term heart failure PMC.
2. Myocardial Remodeling and Repair After Myocardial Infarction
Core mechanism: Downregulate matrix metalloproteinase (MMP-9), reduce extracellular matrix degradation, inhibit collagen deposition in the infarct zone and ventricular wall thinning; promote M2 macrophage polarization, accelerate injury repair.
Research evidence: In myocardial infarction models, SR9009 reduces MMP-9 expression in the infarct border zone, decreases CD45+CD11b+Ly6G+ neutrophil infiltration, improves myocardial survival rates, and enhances left ventricular ejection fraction (LVEF) and shortening fraction (FS).
Application direction: As a candidate strategy for post-myocardial infarction adjunctive therapy, used in combination with antiplatelet and statin drugs to reduce adverse remodeling.
3. Viral myocarditis protection
Core mechanism: Alleviating myocardial inflammation by inhibiting the TLR4/NF-κB pathway, reducing virus replication-related oxidative stress, and protecting mitochondrial function in cardiomyocytes.
Research Evidence: In a mouse coxsackievirus B3 (CVB3) myocarditis model, SR9009 reduced serum troponin I (cTnI) and CK-MB levels, decreased inflammatory infiltration and necrotic areas in myocardial tissue, and improved cardiac function.
Application significance: It provides a new target for anti-inflammatory and myocardial protection in viral myocarditis, particularly suitable for immunomodulation in severe cases.
Application in Osteoarthritis Models
1.Research background and purpose
Osteoarthritis is a common chronic joint disease, mainly manifested as joint pain, stiffness, limited movement and joint deformity, etc., seriously endangering the quality of life of middle-aged and elderly people.
Liposome SR9009 injection has been studied for the treatment of osteoarthritis, aiming to slow down the degradation of extracellular matrix of articular chondrocytes in mice with osteoarthritis, inhibit chondrocyte hypertrophy, decomposition and apoptosis, and alleviate articular cartilage injury and inflammation.
2.Experimental method
The SR9009 liposome was prepared by emulsification and ultrasound. The bilayer formed by lecithin was used as the carrier for loading the SR9009 molecule. Taking C57/BL6 mice as the experimental subjects, the mouse model of osteoarthritis was induced by the meniscus instability method. In the second week after obtaining the model, SR9009 liposome was injected into the articular cavity once a week for 6 consecutive weeks.
3.Experimental results and conclusions
The morphological changes of articular cartilage in mice were evaluated using the OARSI scoring system, and the expression of immunohistochemical-related cartilage markers and inflammation-related factors was analyzed.
The results showed that liposome SR9009 could slow down the degradation of extracellular matrix of articular chondrocytes in mice with osteoarthritis, inhibit chondrocyte hypertrophy, decomposition and apoptosis, effectively alleviate articular cartilage injury and inflammation in mice with osteoarthritis, and had broad application prospects.
Application in Cognitive Impairment Models Related to Sleep Deprivation
Laparotomy in rats with acute rapid eye movement (REM) sleep deprivation models can lead to the impairment of hippocampal working memory, which may be related to the decreased expression of REV-ERB α and BMAL1 in the hippocampus and the increased inflammatory response. SR9009 was studied to explore its protective effect on hippocampal working memory in rats with acute REM sleep deprivation model after laparotomy and its possible mechanism.
2. Experimental method
Ninety SD rats were randomly divided into the control group, the sleep deprivation group, the laparotomy exploration surgery group, the sleep deprivation + laparotomy exploration surgery group, and the sleep deprivation + laparotomy exploration surgery + SR9009 group. In the sleep deprivation + laparotomy + SR9009 group, rats were given REM sleep deprivation for 96 hours and then underwent laparotomy.
From the day of the operation to the fifth day after the operation, 100mg/kg SR9009 was intraperitoneally injected every day.The relevant indicators were detected by methods such as behavioral experiments, Western blotting experiments, enzyme-linked immunosorbent assay (ELISA) experiments and immunofluorescence staining.
From the 1st to the 5th day after the operation, the positioning space exploration training was conducted to record the positioning escape latency of the rats. On the 5th day after the operation, the positioning space exploration experiment was performed to record the number of times the rats crossed the original platform position. The results showed that the escape latency of the sleep deprivation + exploratory laparotomy + SR9009 group was shorter than that of the sleep deprivation + exploratory laparotomy group, and the number of times crossing the original platform position increased. Meanwhile, SR9009 can reduce the levels of inflammatory factors interleukin (IL) -1β and IL-6 in the hippocampus, increase the number of neurons in the hippocampal region, and weaken the activation of astrocytes. This indicates that the use of SR9009 can reduce the impairment of hippocampal working memory in rats with acute REM sleep deprivation model after laparotomy.
Application in the Retinal Pigment Epithelium Injury Model
Retinal pigment epithelium (RPE) atrophy is the main manifestation of dry age-related macular degeneration (AMD), often leading to blindness in the elderly. Oxidative stress is one of the main factors leading to RPE injury. SR9009 injection, as a REV-ERB α agonist, has been studied for protecting the retinal pigment epithelium from damage, providing a potential target for the development of treatment methods for dry AMD.
2. Experimental method
REV-ERB α -deficient (Rev-erb α⁻/⁻) mice, wild-type (WT) control groups, and C57BL/6J mice were selected. The mouse model of RPE injury was induced by intravenous injection of sodium iodate (NaIO₃). After injection of NaIO₃ in C57BL/6J mice, intraperitoneal injection of SR9009 or solvent was given respectively.
The relevant indicators were detected by methods such as fundus imaging, optical coherence tomography (OCT), immunohistochemical staining, RNA and protein expression analysis, and chromatin immunoprecipitation (ChIP) assay.
Fundus imaging and OCT results showed that after injection of NaIO₃ in Rev-erb α⁻/⁻ mice, the RPE injury area was larger and the retinal layer structure disorder was more severe. In C57BL/6J mice given SR9009, the RPE injury area was significantly reduced, and the number of apoptotic RPE cells decreased. Meanwhile, SR9009 can increase the RNA and protein expression of antioxidant genes (such as Nrf2, SOD1 and SOD2). The ChIP experiment identified Nrf2 as the direct transcriptional target of REV-ERB α. This indicates that REV-ERB α regulates RPE damage by regulating Nrf2, and SR9009 can protect RPE from oxidative damage, which is expected to become a potential drug for the treatment of dry AMD.
Potential application value drives development
In the field of metabolic diseases
In the research of metabolic diseases such as obesity and type 2 diabetes, SR9009 has demonstrated the ability to regulate lipid metabolism and glucose metabolism, which can reduce cholesterol and triglyceride levels in the blood, decrease fat accumulation, and improve insulin sensitivity.
These effects provide new ideas for the treatment of metabolic diseases. With the deepening of research, if their safety and efficacy can be verified in the human body, it is expected to become a new type of drug for the treatment of metabolic diseases.
In the field of cardiovascular diseases
Studies have shown that SR9009 can alleviate myocardial ischemia-reperfusion injury in type 2 diabetic rats by up-regulating the SLC7A11/GPX4 axis to limit ferroptosis, thereby protecting myocardial cells. This provides new potential targets for the treatment of cardiovascular diseases.
In the field of sports science
In animal experiments, SR9009 can enhance the exercise endurance of animals, increase the number and activity of mitochondria, and thereby improve the energy production efficiency of cells.
This provides new ideas for athletes' training and performance improvement, but attention should be paid to its legality and safety issues. If its application in the field of sports science can be further studied under the premise of legality and compliance, it will have a positive impact on the training and rehabilitation of athletes.
The current research progress provides support
Scientific research experiments continue to deepen
At present, sr9009 has a certain research foundation in the field of scientific research. Through animal experiments, researchers continue to explore its mechanism of action in the regulation of biological clock, metabolism, inflammation and other aspects, as well as its application effect in different disease models.
These studies provide important theoretical basis and experimental data support for the further development of sr9009.
Potential medical application research
Some studies have begun to focus on the value of SR9009 in potential medical applications, such as the treatment of metabolic syndrome, type 2 diabetes, obesity and cardiovascular diseases, etc. Although these studies are still in the experimental stage at present, with the continuous advancement of the research, it is expected to provide more evidence for the clinical application of SR9009.
Risks and challenges need to be overcome
Safety unknown
The safety and efficacy of SR9009 in humans have not been fully verified. Long-term or excessive use may lead to unknown side effects and health risks, such as affecting the endocrine system, cardiovascular system, etc. This limits its promotion in clinical application and further research is needed to evaluate its safety.
Risk of illegal use
Currently, SR9009 is prohibited from being used for human clinical medical treatment or other non-research purposes, but there are still some unscrupulous merchants illegally selling it as a dietary supplement or performance enhancer. This illegal use not only violates laws and regulations, but also may cause serious harm to the health of users, affecting the reputation and development of SR9009.
High storage and transportation requirements
SR9009 injection has strict requirements for storage and transportation conditions. It needs to be stored at a low temperature (-20℃) to maintain its activity. During transportation, measures such as shock absorption and moisture prevention should be taken to prevent product damage or deterioration. This increases the cost and difficulty of its application and promotion.
FAQ
What is the use of it?
+
-
Animal experiments have shown that it has various effects, including reducing body weight, lowering cholesterol, triglycerides, and low-density lipoprotein, improving sleep and wakefulness regulation, reducing anxiety, decreasing inflammation, and improving heart function .
Does it build muscle?
+
-
Although it is not directly associated with muscle growth, its ability to enhance stamina plays a critical role in muscle performance research. By increasing endurance, it enables test subjects to sustain physical exertion for longer periods, indirectly supporting lean muscle development.
What does it do to testosterone?
+
-
Moreover, it, an NR1D1 agonist, augmented testosterone production in TM3 cells via elevated expression of steroidogenic genes (StAR, Cyp11a1 and Hsd17b3). Conversely, Nr1d1 knockdown inhibited testosterone accumulation and attenuated steroidogenic gene expression.
Does it affect sleep?
+
-
These studies suggest that it and other synthetic REV-ERB agonists can alter the circadian rhythm in rodents (and likely to do this in humans) which has implications for sleep, metabolic issues and potentially mental health problems.
Hot Tags: sr9009 injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 2 Bromo 9 9 dimethyl 5 phenyl 9H fluorene, 3-Bromochrysene, 2 5 Dihydroxybenzaldehyde, 9 phenyl 7 9 dihydrobenzo g indolo 2 3 b carbazole, 1-Bromo-2-chloronaphthalene, 1 Butanesulfonic acid 1 1 2 2 3 3 4 4 4 nonafluoro benzo b naphtho 1 2 d furan 3 yl ester